Division of Plasma Cell Neoplasias

The Division of Plasma Cell Neoplasias is focused on research and clinical care for plasma cell disorders including multiple myeloma, Waldenström's macroglobulinemia, and amyloidosis. For more than four decades, Dana-Farber has led bench-to-bedside research that has had tremendous impact on our understanding of these diseases and improving patient outcomes. As a high-volume center, our clinical teams are experienced in planning treatment and delivering extraordinary care to patients with multiple myeloma, Waldenström's macroglobulinemia, and amyloidosis.

The Division also involves the Center for Early Detection and Interception of Blood Cancers, which is focused on precursor conditions, including plasma cell disorders such as MGUS and smoldering multiple myeloma. The goals of the Center for Early Detection include studying optimal screening methods, performing cutting edge lab-based and clinical research, delivering quality patient care, with the ultimate goal of preventing patients from developing blood cancers.

Division Leadership

Jacob Laubach, MD, MPP, Chief, Division of Plasma Cell Neoplasias

Clinical Programs in the Division

Jerome Lipper Multiple Myeloma Center
Bing Center for Waldenström's Macroglobulinemia
Amyloidosis Program
Center for Early Detection and Interception of Blood Cancers